Tango Therapeutics Newsroom

Cantor Fitzgerald Reiterates Overweight on Tango Therapeuticsto Overweight

BenzingaDec 5 21:37

Tango Therapeutics Analyst Ratings

BenzingaDec 5 21:35 · Ratings

Express News | Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BreakingsDec 3 20:00

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango TherapeuticsDec 3 13:00

Tango Therapeutics Granted FDA Orphan Designation Status For "Small Molecule Inhibitor of PRMT5 (Protein Arginine Methyl Transferase 5)" Treatment Of Pancreatic Cancer

BenzingaNov 27 22:59

Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Tango TherapeuticsNov 27 13:00

Tango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According to Hedge Funds

Yahoo FinanceNov 23 23:26

Versant Ventures Unveils Pep2Tango Therapeutics Inc.

BusinesswireNov 21 21:00

Independent Director of Tango Therapeutics Mace Rothenberg Buys 400% More Shares

Simply Wall StNov 21 18:27

The Analyst Landscape: 5 Takes On Tango Therapeutics

BenzingaNov 12 02:00

B.Riley Financial Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Cuts Target Price to $8

Futu NewsNov 11 21:31 · Ratings

Tango Therapeutics(TNGX.US) 10% Shareholder Sells US$8.44 Million in Common Stock

$Tango Therapeutics(TNGX.US)$ 10% Shareholder EcoR1 Capital, LLC sold 2.7 million shares of common stock on Nov 6, 7, 2024 at an average price of $3.1243 for a total value of $8.44 million.Source:

Futu NewsNov 9 08:31

Guggenheim Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $8

Futu NewsNov 8 20:31 · Ratings

H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $13

Futu NewsNov 8 20:31 · Ratings

Promising Developments and Strategic Shifts at Tango Therapeutics: A Buy Rating With a $13 Price Target

TipRanksNov 8 20:22 · Ratings

Tango Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Yahoo FinanceNov 8 19:05

Positive Outlook for Tango Therapeutics: Promising TNG462 Data and Strategic Focus

TipRanksNov 8 15:27

Tango Therapeutics(TNGX.US) Insider Sells US$9.67 Million in Common Stock

$Tango Therapeutics(TNGX.US)$ Insider Boxer Capital Management, LLC sold 3.08 million shares of common stock on Nov 6, 2024 at an average price of $3.14 for a total value of $9.67 million. This

Futu NewsNov 8 10:34

Tango Therapeutics Is Maintained at Buy by Guggenheim

Dow JonesNov 8 03:37 · Ratings

Tango Therapeutics Analyst Ratings

BenzingaNov 8 03:27 · Ratings